ADMA
ADMA Biologics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
14.90
PEG
—
P/B
4.63
P/S
4.33
EV/EBITDA
11.13
DCF Value
$-123.45
FCF Yield
1.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
57.4%
Operating Margin
37.5%
Net Margin
28.8%
ROE
35.0%
ROA
23.5%
ROIC
27.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $139.2M | $49.4M | $0.20 |
| FY 2025 | $510.2M | $146.9M | $0.60 |
| Q3 2025 | $134.2M | $36.4M | $0.15 |
| Q2 2025 | $122.0M | $34.2M | $0.14 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.82
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.